PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 11, 202652 citationsOpen Access

Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy

View Full Paper
DJDaniel P. JudgeKAKevin AlexanderFCFrancesco Cappelli

Key Points

  • Acoramidis reduced the composite outcome of all-cause mortality and cardiovascular hospitalization compared to placebo.
  • The early effect was primarily due to a reduction in cardiovascular hospitalizations among participants.
  • This analysis focuses on transthyretin amyloid cardiomyopathy, a serious heart condition.
  • These findings may indicate a promising intervention for managing ATTR-CM and improving patient outcomes.

Abstract

In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy ATTRibute-CM; NCT03860935).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Judge et al. (2025) studied this question.

synapsesocial.com/papers/69b19b8dd8cfb334e198cc15https://doi.org/10.1016/j.jacc.2024.11.042
Ask AI
Helpful
Bookmark
Share
View Full Paper